



14th August 2023

To
The Corporate Relations Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001.

Dear Sir/Madam,

Sub: Submission of Un-Audited Financial Results under regulation 30 and 33 of SEBI (LODR) Regulations, 2015.

Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH

This is to inform you that the Board of Directors of the Company at its meeting held on this day i.e. 14th August 2023 has, inter alia, approved Un-Audited Financial Results for the First Quarter ended on 30th June, 2023 as recommended by the Audit Committee and reviewed by the Statutory Auditors.

Further please find enclosed herewith the following documents in terms of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015:

1. Un-Audited Financial Results of the Company for the First Quarter ended on 30th June, 2023.
2. Limited Review Report for the Un-Audited Standalone Financial Results issued for the First Quarter ended on 30th June, 2023.

The meeting commenced at 04.00 P.M. and concluded at 04.30 P.M.

This is for your information and necessary records.

Thanking you,

Yours faithfully,
For Oxygenta Pharmaceutical Limited
(Formerly known as S.S. Organics Ltd.)

Name: Sai Sudhakar Vankineni

Designation: Managing Director

DIN.: 00733001

OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S.S. ORGANICS LIMITED)

(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: cs@oxygentapharma.com, info@oxygentapharma.com. Website: www.oxygentapharma.com

CIN: L24110TG1990PLC012038

OXYGENTA PHARMACEUTICAL LIMITED
(Formerly Known as S. S. ORGANICS LIMITED)
CIN : L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State
Corp Office: Plot no: 43, Sy no. 55 to 58, The Park View 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500032
Website: www.oxygentapharma.com, Email Ids: md@oxygentapharma.com , cs@oxygentapharma.com , Phone Number: 040- 23559938


UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2023

(Amt. in Rs. Lakhs Except EPS)

SL No	PARTICULARS	QUARTER ENDED			YEAR ENDED
		30.06.2023	31.03.2023	30.06.2022	31.03.2023
		Un Audited	Audited	Un Audited	Audited
	Income from operations				
1	a) Revenue from Operations	686.39	818.58	889.32	3,098.75
	b) Other Income	-	0.10	-	1.78
	Total Income from Operations (Net)	686.39	818.68	889.32	3,100.52
2	Expenses:				
	a. Consumption of Materials	808.80	734.77	760.68	2,812.61
	b. Purchase of Stock in trade	-	-	-	-
	c. Change in inventories of finished goods, WIP & stock-in-trade	(107.07)	(77.76)	(77.21)	(463.48)
	d.Direct Manufacturing Expenses	294.32	316.59	243.46	1,172.55
	e. Employment Benefit Expenses	17.80	41.95	14.44	124.23
	f. Finance Cost	29.41	94.06	24.90	148.75
	g. Depreciation and Amortization Expenses	50.00	85.18	40.00	205.18
	h. Other Expenditure	36.11	27.72	52.43	164.53
	Total Expenses	1,129.37	1,222.50	1,058.71	4,164.36
3	Profit/(Loss) from Operations before Exceptional Items and Tax	(442.99)	(403.82)	(169.40)	(1,063.83)
4	Exceptional Items - (Exp) / Income	(12.89)	(5.43)	-	(73.43)
5	Profit / (loss) Before Tax	(455.88)	(409.25)	(169.40)	(1,137.27)
6	Tax Expenses				
	Current Tax	-	-	-	-
	Deferred Tax	-	19.83	-	19.83
7	Net Profit/(Loss) for the period (A)	(455.88)	(429.08)	(169.40)	(1,157.10)
8	Other comprehensive income				
	a) (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	b) (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income	(455.88)	(429.08)	(169.40)	(1,157.10)
9	Paid up Equity Share Capital				
	(Face value of Equity Rs 10/- per share)	3,348.35	1,420.13	1,420.13	1,420.13
10	Basic & Diluted Earning per share (Rs.10/- per share) on (A) above				
	(a) Basic	(1.65)	(3.02)	(1.19)	(8.15)
	(a) Diluted	(1.65)	(3.02)	(1.19)	(8.15)

NOTES:

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 14th August 2023 at Corporate office, Plot No. 43, Sy.no. 55 to 58, The park view, 1st floor, lumbini Avenue, Gachibowli, Hyderabad 500032.
- The Statutory Auditors have Carried out Limited Review of the above results for the Quarter ended 30th June,2023
- The above statement of financial Results are prepared in accordance with the Indian Accounting Standards (Ind- AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- The Company operates in a single segment and the results pertain to a single segment.
- The Standalone Financial Results are reviewed by the Statutory auditors of the company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.



OXYGENTA PHARMACEUTICAL LIMITED
(Formerly Known as S. S. ORGANICS LIMITED)

V Sai Sudhakar

SAI SUDHAKAR VANKINENI

Managing Director

DIN :00733001

Place: Hyderabad
Date: 14-Aug-2023



Independent Auditor's Review Report on Unaudited Quarterly Financial Results pursuant to the Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To the Board of Directors of
OXYGENTA PHARMACEUTICAL LIMITED
(Formerly known as S. S. ORGANICS LIMITED)

We have reviewed the accompanying Statement of Unaudited Financial Results ("the Statement") of **OXYGENTA PHARMACEUTICAL LIMITED** ("the Company") for the quarter ended June 30, 2023, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52 read with Regulation 63 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations") including relevant circulars issued by the SEBI from time to time.

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement..

for Gowri Shankar & Associates
Chartered Accountants
Firm Registration No. 015625S

S. Gowri Shankar

Gowri Shankar Seshapu

Partner

M No. 234732

UDIN: **23234732-BGQERTG774**

Date: 14-08-2023

Place: Hyderabad

